Pfizer (NYSE: PFE) is a great example, with its shares down around 57% below the previous high. When a stock plunges as much ...

Seongnam: SK bioscience, a global vaccine and biotech company, has announced that the Supreme Court of Korea has ruled in its ...

Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...

Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

SK bioscience wins patent lawsuit against Pfizer over pneumococcal vaccine in Korea: Gyeonggi-do, Republic of Korea Friday, May 23, 2025, 10:00 Hrs [IST] SK bioscience, a global i ...

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K. regulators cleared Sarepta to restart an Elevidys study and Altos Labs ...

The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in ...

Overview of RNA Therapeutics MarketThe Global RNA Therapeutics Market is valued at USD 10.9 Billion in 2024 and is projected ...

Pfizer has struck a high-stakes deal with 3SBio to license SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside of China. Unlike current drugs that hit only PD-1, this antibody aims at two ...

The global monoclonal antibodies market is poised for robust expansion, projected to surge from USD 208.32 billion in 2022 to USD 647.01 billion by 2032, reflecting a CAGR of 12% over the forecast ...

Moscicki previously served as the deputy center director for science operations at the FDA’s Center for Drug Evaluation and ...

Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.